Literature DB >> 16586449

Long-circulating liposomal contrast agents for magnetic resonance imaging.

Ananta Laxmi Ayyagari1, Xiaodong Zhang, Ketan B Ghaghada, Ananth Annapragada, Xiaoping Hu, Ravi V Bellamkonda.   

Abstract

Contrast-enhanced magnetic resonance imaging (CE-MRI) is a dynamic technique for imaging vasculature. However, the currently used gadolinium (Gd) chelates, such as Gd-DTPA, restrict the time window for image acquisition due to their rapid elimination from blood and their rapid diffusion into the extravascular space, which prevents their use in steady-state imaging, particularly for MR angiography (MRA). The goal of this study was to prepare long-circulating polyethylene glycol-bearing ((PEG)ylated) liposomes encapsulating Gd chelate, and characterize and demonstrate their utility for MRA. The liposomes were prepared by hydrating a mixture of lipids with gadodiamide (Omniscan). The liposomes were sized down to around 100 nm by extruder and exhaustively dialysed to remove the unencapsulated gadodiamide. The Gd liposomes exhibited a significant sustained (>4 hr) contrast enhancement of the vasculature with improved spatial details in a rat model with little leakage relative to Gd-DTPA controls as shown by MRI. We suggest that such long-circulating liposomal formulations allow for high spatial resolution imaging without the confounding effects of clearance and extravascular diffusion of the agent complicating the data and image analysis. Copyright (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16586449     DOI: 10.1002/mrm.20846

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  25 in total

1.  In vivo assembly of nanoparticle components to improve targeted cancer imaging.

Authors:  Steven D Perrault; Warren C W Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

Review 2.  Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.

Authors:  Aaron Joseph L Villaraza; Ambika Bumb; Martin W Brechbiel
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 3.  Imaging the paediatric lung: what does nanotechnology have to offer?

Authors:  K L Ordidge; B A Duffy; J A Wells; T L Kalber; S M Janes; M F Lythgoe
Journal:  Paediatr Respir Rev       Date:  2011-08-04       Impact factor: 2.726

4.  Gd Complexes of DO3A-(Biphenyl-2,2'-bisamides) Conjugates as MRI Blood-Pool Contrast Agents.

Authors:  Ki-Hye Jung; Hee-Kyung Kim; Ji-Ae Park; Ki Soo Nam; Gang Ho Lee; Yongmin Chang; Tae-Jeong Kim
Journal:  ACS Med Chem Lett       Date:  2012-10-23       Impact factor: 4.345

Review 5.  Noninvasive imaging of peripheral nerves.

Authors:  Gautam Rangavajla; Nassir Mokarram; Nazanin Masoodzadehgan; S Balakrishna Pai; Ravi V Bellamkonda
Journal:  Cells Tissues Organs       Date:  2015-03-04       Impact factor: 2.481

6.  High-resolution magnetic resonance angiography in the mouse using a nanoparticle blood-pool contrast agent.

Authors:  Gabriel P Howles; Ketan B Ghaghada; Yi Qi; Srinivasan Mukundan; G Allan Johnson
Journal:  Magn Reson Med       Date:  2009-12       Impact factor: 4.668

Review 7.  Nanovehicular intracellular delivery systems.

Authors:  Ales Prokop; Jeffrey M Davidson
Journal:  J Pharm Sci       Date:  2008-09       Impact factor: 3.534

Review 8.  Paramagnetic liposome nanoparticles for cellular and tumour imaging.

Authors:  Nazila Kamaly; Andrew D Miller
Journal:  Int J Mol Sci       Date:  2010-04-15       Impact factor: 5.923

9.  Strategies for Target-Specific Contrast Agents for Magnetic Resonance Imaging.

Authors:  Sashiprabha M Vithanarachchi; Matthew J Allen
Journal:  Curr Mol Imaging       Date:  2012-10-01

10.  New dual mode gadolinium nanoparticle contrast agent for magnetic resonance imaging.

Authors:  Ketan B Ghaghada; Murali Ravoori; Divya Sabapathy; James Bankson; Vikas Kundra; Ananth Annapragada
Journal:  PLoS One       Date:  2009-10-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.